2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Treatment Considerations, Supportive Care, Biological Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Diseases, Bleeding and Clotting, Thromboembolism, Thrombocytopenias, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, MPN, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Pediatric, Pregnant
PAPER

4865 Biologic therapy and risk of venous thromboembolism in hospitalized patients with inflammatory bowel disease: A propensity-matched trinetx analysis

Zaid Almubaid, MD, Zachrieh Alhaj, MD2, Yahya Haj Hamad3, Yakob Zumlot, BS4, Hesham Abowali, MD5
1 Baylor College of Medicine, Houston, United States
2 University of Texas Health Science Center Houston, Houston, United States
3 University of Texas Medical Branch, Galveston, United States
4 University of Houston, Houston, United States
5 University of Texas Medical Branch, Galveston, United States

Venous thromboembolism (VTE) is a leading cause of preventable morbidity and mortality among hospitalized medical patients, and patients with inflammatory bowel disease (IBD) carry an elevated risk due to chronic inflammation and corticosteroid exposure. Prior research suggests anti-tumor necrosis factor (anti-TNF) therapy lowers VTE risk relative to corticosteroids, but whether broad biologic exposure or biologic class specifically differentiates thrombotic risk remains unclear. In this study, we examined inpatient and 90-day VTE risk associated with biologic therapy in hospitalized adults with IBD, and separately compared anti-TNF versus non-TNF biologic agents.

We performed a retrospective propensity-matched cohort study using the TriNetX US Collaborative Network, a realworld database aggregating electronic health record data across participating health care organizations. Adults hospitalized for any cause with a diagnosis of Crohn's disease or ulcerative colitis who were receiving biologic therapy within 90 days prior to admission were identified and matched 1:1 to hospitalized IBD patients not receiving biologic therapy (n=4,032 per arm), using propensity matching on age, sex, comorbidity burden, IBD subtype, and corticosteroid use within the same 90-day window, the latter used as a proxy for underlying disease control. In a secondary analysis, patients on anti-TNF agents were matched 1:1 to patients on non-TNF biologics (n=827 per arm) using the same approach. The primary outcome was a composite VTE event during the index hospitalization. Secondary outcomes included VTE within 90 days of discharge, major gastrointestinal bleeding, colectomy, and 90-day hospital readmission.

Biologic use was associated with significantly lower inpatient VTE compared with non-biologic use (0.69% vs 1.14%; RR 0.61, 95% CI 0.38–0.97; p=0.036), consistent with prior findings that biologic therapy may reduce thrombotic risk. 90-day post discharge VTE incidence did not differ significantly between groups (2.41% vs 2.65%; p=0.48), suggesting the protective association was largely confined to the acute inpatient period. Biologic users had significantly higher rates of major GI bleeding (9.80% vs 7.61%; p=0.0005), colectomy (4.84% vs 1.51%; p<0.0001), and 90-day readmission (21.4% vs 14.7%; p<0.0001) compared with non-biologic users. These differences may reflect underlying disease severity rather than a direct effect of biologic therapy, as biologics are more often prescribed in refractory or severe disease. In the anti-TNF versus non-TNF secondary analysis, anti-TNF recipients showed a nonsignificant trend toward higher 90-day VTE compared with non-TNF recipients (3.14% vs 1.69%; RR 1.86, 95% CI 0.98–3.53; p=0.055). Colectomy rates were identical between the anti-TNF and non-TNF subgroups (4.23% vs 4.23%), which may indicate comparable disease severity between the two subgroups.

In this large propensity-matched real-world cohort, biologic therapy was associated with reduced inpatient VTE risk in hospitalized patients with IBD, but this association did not extend to the post discharge period. Anti-TNF therapy showed a nonsignificant trend toward higher 90-day VTE risk compared with non-TNF biologics, despite similar colectomy rates between groups arguing against confounding by severity. A limitation of this approach is that the 90-day corticosteroid use window cannot fully distinguish an admission driven by an active flare from an unrelated admission occurring soon after one, a constraint inherent to real world data that should be considered when interpreting disease severity matching.

Zaid Almubaid, MD: No relevant conflicts of interest to declare.